Average pre-risperidone GAF scores were 32.2 (+/-5.4) and for the control group were 33.9 (+/-6). Average post-risperidone GAF scores were 32.2 (+/-4.3) and for the control group were 34.3 (+/-5.4), a significant difference (t=2.255, df=110, p=0.3). Note: this scoreline did not control for baseline scores. Also, a mixed-model repeated-measures analysis found no significant group differences in monthly GAF scores when taking into account pre-risperidone scores over the course of the study period. Because the risperidone treatment group was defined by treatment initiation, potential biasing was evaluated using life table analyses from which no medication prescription was the failure point based on the Kaplan-Meier product-limit method.